Marshall Wace North America’s KalVista Pharmaceuticals KALV Stock Holding History

Marshall Wace North America’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-22,136	Closed	-$530K	–	1586
2021 Q2	$530K	Sell	22,136 -76,042	-77%	-$1.99M	﹤0.01%	1162
2021 Q1	$2.52M	Buy	+98,178	New	+$2.58M	0.01%	757
2019 Q2	–	Sell	-6,126	Closed	-$175K	–	1368
2019 Q1	$175K	Buy	+6,126	New	+$133K	﹤0.01%	1017

Other funds holding KALV

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace North America's KALV Position: Q3 2021 in Review

Marshall Wace North America sold out of KalVista Pharmaceuticals (KALV) in Q3 2021, closing a stake of 22,136 shares — an estimated $530K sold.

Marshall Wace North America first reported a position in KALV in Q1 2019 and held it in 3 quarters. The position peaked at $2.52M in Q1 2021. 105 funds tracked by Wall St. Rank hold KALV as of Q3 2021.

Marshall Wace North America reported no remaining KalVista Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Marshall Wace North America sold 22,136 KalVista Pharmaceuticals shares in Q3 2021, an estimated $530K.
Marshall Wace North America first reported a position in KalVista Pharmaceuticals in Q1 2019 and held it in 3 quarters.
Marshall Wace North America's KalVista Pharmaceuticals position peaked at $2.52M in Q1 2021.
105 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.